

5'-GTATGTTG-3' (wt) → 5'-GTATATTG-3' (Ps) → 5'-GTATAATG-3' (UV-5)  
3'-CATAACAAC-5' 3'-CATATAAC-5' 3'-CATATTAC-5'

Another interesting observation from our data set in this regard is that adjacent sequences occasionally act to abolish what should be a preferred binding site. One such region (Figure 2, right) may assume the Z conformation in supercoiled plasmids (Barton & Raphael, 1985). In general, however, the interactions of [(Phen)<sub>2</sub>Cu<sup>1+</sup>] can best be rationalized in terms of present knowledge of effects of sequence on the local conformation of B-form DNA.

# ACKNOWLEDGMENTS

We thank Dr. William Marzluff and co-workers for advice on DNA cloning and sequencing techniques.

# REFERENCES

- Barton, J. K. (1986) *Science (Washington, D.C.)* 233, 727-733.
- Barton, J., & Raphael, A. (1985) *Proc. Natl. Acad. Sci. U.S.A.* 82, 6460-6464.
- Calladine, C. R. (1982) *J. Mol. Biol.* 161, 343-352.
- Cartwright, I. A., & Elgin, S. (1982) *Nucleic Acids Res.* 10, 5835-5852.
- Dickerson, R. E. (1983) *J. Mol. Biol.* 166, 419-441.
- Dickerson, R. E., & Drew, H. (1981) *J. Mol. Biol.* 149, 761-786.

- Drew, H., & Travers, A. (1984) *Cell (Cambridge, Mass.)* 37, 491-502.
- Feigon, J., Denny, W. A., Leupin, W., & Kearns, D. R. (1984) *J. Med. Chem.* 27, 450-464.
- Goodsell, D., & Dickerson, R. E. (1986) *J. Med. Chem.* 29, 727-733.
- Jesse, B., Gargiulo, G., Razvi, F., & Worcel, A. (1982) *Nucleic Acids Res.* 10, 5823-5834.
- Kopka, M. L., Yoon, C., Goodsell, D., Pjura, P., & Dickerson, R. E. (1985) *Proc. Natl. Acad. Sci. U.S.A.* 82, 1376-1380.
- Kuwabara, M., Yoon, C., Goynes, T., Thederhan, T., & Sigman, D. (1986) *Biochemistry* 25, 7401-7408.
- Pope, L., Reich, K., Graham, D., & Sigman, D. (1982) *J. Biol. Chem.* 257, 12121-12128.
- Sigman, D. (1986) *Acc. Chem. Res.* 19, 180-186.
- Sigman, D., Spassky, A., Rimsky, S., & Buc, H. (1985) *Biopolymers* 24, 183-197.
- Sittman, D. B., Graves, R. A., & Marzluff, W. F. (1983) *Nucleic Acids Res.* 11, 6679-6696.
- Spassky, A., & Sigman, D. S. (1985) *Biochemistry* 24, 8050-8056.
- Suggs, W., & Wagner, R. (1986) *Nucleic Acids Res.* 14, 3703-3715.
- Tung, C. S., & Harvey, S. (1986) *J. Biol. Chem.* 261, 3700-3709.
- Wilson, W. D., Wang, Y.-H., Kusuma, S., Chandrasekaran, S., Yang, N. C., & Boykin, D. W. (1985) *J. Am. Chem. Soc.* 107, 4989-4995.

## The Receptor Site for the Bee Venom Mast Cell Degranulating Peptide. Affinity Labeling and Evidence for a Common Molecular Target for Mast Cell Degranulating Peptide and Dendrotoxin I, a Snake Toxin Active on K<sup>+</sup> Channels<sup>†</sup>

Hubert Rehm, Jean-Noël Bidard, Hugues Schweitz, and Michel Lazdunski\*

Centre de Biochimie, Centre National de la Recherche Scientifique, Parc Valrose, 06034 Nice Cedex, France

Received November 18, 1987; Revised Manuscript Received December 23, 1987

**ABSTRACT:** The mast cell degranulating peptide (MCD) and dendrotoxin I (DTX<sub>I</sub>) are two toxins, one extracted from bee venom, the other one from snake venom, that are thought to act on voltage-sensitive K<sup>+</sup> channels. Binding sites for the two toxins have been solubilized. The solubilized sites were stable and retained their high affinity for <sup>125</sup>I-DTX<sub>I</sub> and <sup>125</sup>I-MCD (*K*<sub>d</sub> ≈ 100 pM). Interactions were found between MCD and DTX<sub>I</sub> binding sites in the solubilized state, establishing that the two different toxins act on the same protein complex. This conclusion was strengthened by the observations (i) that conditions of solubilization that eliminated <sup>125</sup>I-MCD binding activity also eliminated <sup>125</sup>I-DTX binding activity while both types of activities were preserved in the presence of K<sup>+</sup> or Rb<sup>+</sup> and (ii) that binding components for the two types of toxins had similar sedimentation coefficients and copurified in partial purifications. A component of the receptor protein for <sup>125</sup>I-MCD has been identified; it has a *M*<sub>r</sub> of 77 000 ± 2000. This polypeptide was similar to or identical in molecular weight with that which serves as a receptor for DTX<sub>I</sub> (*M*<sub>r</sub> 76 000 ± 2000).

**T**he mast cell degranulating peptide (MCD)<sup>1</sup> is a basic toxin of 22 amino acids (Habermann, 1972). Aside from its mast cell degranulating activity, the peptide also acts in the central

nervous system. Depending on the concentrations injected, MCD induces hippocampal  $\theta$  rhythms associated with arousal

<sup>†</sup> This work was supported by the Centre National de la Recherche Scientifique, the Ministère de la Défense (Grant DRET 85138), and the Fondation pour la Recherche Médicale. H.R. is a stipendiat of the Deutsche Forschungsgemeinschaft.

\* Address correspondence to this author.

<sup>1</sup> Abbreviations: MCD, mast cell degranulating peptide; DTX<sub>I</sub>, dendrotoxin I; DMS, dimethyl sulfoxide; SDS, sodium dodecyl sulfate; Hepes, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; Tris, tris-(hydroxymethyl)aminomethane; EDTA, ethylenediaminetetraacetic acid; DEAE, diethylaminoethyl; WGA, wheat germ agglutinin.

or/and convulsions and epileptogenic crisis (Bidard et al., 1987a). Recent electrophysiological evidence has shown that the peptide induces hippocampal long-term potentiation, which is usually associated with information storage and memory (Cherubini et al., 1987).

Dendrotoxins are neurotoxins of the venom of *Dendroaspis* snakes (Harvey et al., 1984). These basic polypeptides ( $M_r \sim 7000$ ) are homologous to protease inhibitors and facilitate evoked neurotransmitter release (Harvey & Karlsson, 1982; Harvey & Anderson, 1985). Recent research has provided data strongly suggesting that blockade of  $K^+$  channels accounts for the facilitatory effects of the toxins (Penner et al., 1986; Weller et al., 1985). DTX<sub>1</sub> is the most potent member of the dendrotoxin family known until now.

High-affinity MCD binding sites (Taylor et al., 1984) have been identified in brain membranes, and it has been shown recently that DTX<sub>1</sub> was capable of inhibiting <sup>125</sup>I-MCD binding to both brain membranes and slices (Bidard et al., 1987b). The inhibition was particularly potent at the level of hippocampus (Bidard et al., 1987b).

The purpose of this paper is to establish definitely by use of the solubilized toxin receptor that the snake toxin DTX<sub>1</sub> and the bee venom toxin MCD are both binding to the same protein complex, which is presumably closely associated with a  $K^+$  channel. The polypeptide chains bearing the MCD and DTX<sub>1</sub> binding sites have been identified in cross-linking experiments.

#### EXPERIMENTAL PROCEDURES

**Materials.** MCD was prepared as previously described (Taylor et al., 1984; Bidard et al., 1987b). DTX<sub>1</sub> was purified from the venom of *Dendroaspis polylepis* by gel filtration on Sephadex G-50, followed by ion-exchange chromatography on a Spherogel TSK SP 5PW column. Minor impurities were eliminated by reverse-phase chromatography on a Lichrosorb RP-18 column from Merck, with a linear gradient between 10% and 40% acetonitrile. The biological activity of the DTX<sub>1</sub> preparation was checked by its toxicity after intraventricular injection into mouse brain (lethal dose of 4 ng/g of body weight) (Schweitz, 1984). The polyamine compound 48/80 that stimulates mastocytes degranulation was from Sigma.

**Iodination of MCD and DTX<sub>1</sub>.** <sup>125</sup>I-MCD was prepared as previously described (Taylor et al., 1984). DTX<sub>1</sub> (3 nmol) was incubated for 15 min at room temperature with radiolabeled <sup>125</sup>I-Na (1 nmol) in an Eppendorf tube containing Iodogen (Pierce) (3 nmol) and 100 mM Tris-HCl buffer at pH 7.5. The mixture was loaded on a SP-Sephadex C-25 column (5 mL) equilibrated with 20 mM Tris-HCl buffer at pH 9.4 containing 1 mg/mL bovine serum albumin, 3 mM sodium azide, and 80 mM NaCl. The column was eluted stepwise with 30 mL of the equilibration buffer and then with a buffer containing 355 mM NaCl instead of 80 mM NaCl. The procedure separated native and iodinated peptides. LD<sub>50</sub> values determined by intracisternal injections were nearly identical for <sup>125</sup>I-DTX<sub>1</sub> and unlabeled DTX<sub>1</sub>.

**Preparation of Detergent Extract.** P3 membranes from rat brain prepared as described by Taylor et al. (1984) were suspended in a 10-fold volume of 20 mM NaHepes buffer at pH 7.4 containing 120 mM KCl, 2 mM CaCl<sub>2</sub>, 2 mM MgSO<sub>4</sub>, 10% (v/v) glycerol, 1% (w/v) Triton X-100, and 0.2% (w/v) soybean phospholipid (buffer A) to a protein concentration of 4–5 mg/mL. A volume (1/10) of 20% (w/v) Triton X-100 containing 0.1 mM EDTA, pH 7.4, was then added and the suspension incubated for 1 h at 4 °C. The suspension was centrifuged for 15 min at 10000g and the supernatant for another 60 min at 150000g. The supernatant of the latter

centrifugation is referred to as detergent extract and was used for binding assays. Protein concentrations were determined according to the method of Lowry et al. (1951) using bovine serum albumin as a standard.

**Binding Assays.** <sup>125</sup>I-DTX<sub>1</sub> and <sup>125</sup>I-MCD binding to detergent extracts was determined by a modification of the filter assay described by Bruns et al. (1983). A sample (2–50 μL) of detergent extract was adjusted to a volume of 190 μL with buffer A. <sup>125</sup>I-DTX<sub>1</sub> or <sup>125</sup>I-MCD peptide was added in 10 μL of buffer A, and the mixture was incubated for 20 min at 4 °C. To measure nondisplaceable binding (hereafter referred to as nonspecific binding), parallel incubation mixtures contained in addition 100 nM unlabeled DTX<sub>1</sub> or 1 μM unlabeled MCD for <sup>125</sup>I-DTX<sub>1</sub> or <sup>125</sup>I-MCD peptide binding, respectively. Incubation mixtures (total volume 200 μL) were then diluted with 5–6 mL of ice-cold buffer A and filtrated through GF/B filters coated with 0.5% poly(ethylenimine) at pH 7.5. The filters were then counted in a γ-counter. All binding data were corrected for nonspecific binding and represent the mean of triplicate determinations.

**Sucrose Density Centrifugation.** Linear sucrose gradients [3–20% (w/v)] were prepared in buffer A or in buffer A containing only 4% (v/v) glycerol. The detergent extract (800 μL) was layered on top, and the gradients were centrifuged in a Spinco SW41 Ti rotor at 35 000 rpm and 4 °C for 17 h. Fractions of 0.8 mL were collected and assayed for <sup>125</sup>I-DTX<sub>1</sub> and <sup>125</sup>I-MCD peptide binding. Bovine liver catalase (11.3 S) was detected by enzymatic assay.

**Partial Purification of DTX<sub>1</sub> and MCD Binding Sites.** A column of DEAE-Affi-Gel blue (0.5 × 8.8 cm) was equilibrated with buffer A containing 1 mM EDTA instead of CaCl<sub>2</sub> and MgSO<sub>4</sub> (buffer B). The detergent extract (40–100 mL) was then loaded onto the column. The column was washed with 100 mL of buffer B and eluted with buffer B containing 180 mM KCl instead of 120 mM.

Fractions containing the binding activity were pooled and loaded onto a column of 8 mg/mL wheat germ agglutinin (WGA) coupled to Affi-Gel 10, which had been equilibrated with buffer B. The column was washed with 15 mL of buffer B and then eluted with buffer B containing 50 mM *N*-acetylglucosamine and 0.1% (w/v) Triton X-100 instead of 1% (w/v).

**Cross-Linking of Iodinated Toxins to Rat Brain Synaptic Membrane.** <sup>125</sup>I-MCD (2 nM, 500 Ci/mmol) or <sup>125</sup>I-DTX<sub>1</sub> (0.2 nM, 2000 Ci/mmol) was incubated for 30 min at 4 °C with P3 membranes (0.5 mg of protein) in the absence or in the presence of various concentrations of unlabeled MCD or DTX<sub>1</sub> in a total buffer volume of 500 μL. The buffer used for <sup>125</sup>I-MCD was 20 mM Tris-HCl, pH 7.5, containing 140 mM NaCl, 1.3 mM MgSO<sub>4</sub>, 5 mM KCl, 2.8 mM CaCl<sub>2</sub>, 1 mg/mL bovine serum albumin, and 10 μg/mL compound 48/80. The buffer used for cross-linking experiments with <sup>125</sup>I-DTX<sub>1</sub> was 50 mM Tris-HCl, pH 7.5, containing 140 mM NaCl, 1.3 mM MgSO<sub>4</sub>, 5 mM KCl, and 1 mg/mL bovine serum albumin. The samples were then centrifuged at 10000g for 5 min and washed twice at 4 °C with 500 μL of 50 mM phosphate buffer, pH 8.5. The membranes were resuspended in 500 μL of the latter buffer containing the indicated concentrations of dimethyl suberimidate (DMS)<sup>1</sup> (usually at a final concentration of 0.5 mg/mL). Following incubation at 4 °C for 20 min, the reaction was stopped by washing the membranes repeatedly with 100 mM Tris-HCl buffer at pH 7.4. The membranes were then solubilized in 50 μL of solubilizer (Laemmli, 1970) containing 10 μg/mL soybean trypsin inhibitor, 0.1 mM phenylmethanesulfonyl fluoride, 1 mM




FIGURE 1: Binding of  $^{125}\text{I}$ -DTX<sub>I</sub> and  $^{125}\text{I}$ -MCD peptide to a detergent extract (40–50  $\mu\text{g}$  of protein) of rat brain membranes. (A) Binding of  $^{125}\text{I}$ -MCD peptide. Specific binding ( $\bullet$ ) is the difference between total binding ( $\circ$ ) and nonspecific binding ( $\square$ ). Inset: Scatchard plot of specific binding. (B) Binding of  $^{125}\text{I}$ -DTX<sub>I</sub>. Legend as for (A).

*o*-phenanthroline, and 1 mM iodoacetic acid and analyzed by SDS-polyacrylamide gel electrophoresis (Laemmli, 1970) (4% stacking gel, 8% separating gel). Molecular weight standards were carbonic anhydrase (31 000), ovalbumin (45 000), bovine serum albumin (66 200), phosphorylase B (92 500),  $\beta$ -galactosidase (116 250), and myosin (200 000). After being stained with Coomassie blue R250 (Bio-Rad), gel slabs were dried and autoradiographed with X-Omat AR Kodak diagnostic film.

## RESULTS

**Binding of  $^{125}\text{I}$ -DTX<sub>I</sub> and  $^{125}\text{I}$ -MCD Peptide to Detergent Extract of Brain Membranes. Evidence for a Maintained Interaction between the Snake and the Bee Venom Toxin Receptor Sites in the Solubilized State.** Triton X-100 extracts of rat brain membranes, prepared in the presence of  $\text{K}^+$  and glycerol, showed saturable binding of  $^{125}\text{I}$ -DTX<sub>I</sub> and  $^{125}\text{I}$ -MCD peptide (Figure 1). The binding activity of the detergent extract was stable with a half-life of 3–4 days at 4  $^{\circ}\text{C}$  (not shown). Scatchard analysis (Figure 1, insets) of the binding revealed, for each peptide, a single class of high-affinity binding sites ( $K_D = 96$  pM for  $^{125}\text{I}$ -DTX<sub>I</sub> and  $K_D = 115$  pM for  $^{125}\text{I}$ -MCD peptide). The maximal number of toxin binding sites in the detergent extract was 356 fmol/mg for  $^{125}\text{I}$ -DTX<sub>I</sub> and 168 fmol/mg for  $^{125}\text{I}$ -MCD peptide. These data suggest the presence of about two DTX<sub>I</sub> binding sites per MCD binding site.

Association and dissociation kinetics of  $^{125}\text{I}$ -DTX<sub>I</sub> and  $^{125}\text{I}$ -MCD binding to its solubilized binding sites were also determined.  $^{125}\text{I}$ -DTX<sub>I</sub> (180 pM) bound to its solubilized site (0.355 mg/mL protein) with a half-time of association of 38 s. Binding was essentially complete after 6 min. Dissociation of  $^{125}\text{I}$ -DTX<sub>I</sub> from its solubilized site, in the presence of an excess of unlabeled toxin, had a half-time of 7.7 min. Kinetics of  $^{125}\text{I}$ -MCD binding were faster with a half-time of association of 12 s (21 pM  $^{125}\text{I}$ -MCD, 0.171 mg/mL protein) and a half-time of dissociation of 45 s.

Figure 2 shows that DTX<sub>I</sub>, as MCD itself, inhibits  $^{125}\text{I}$ -MCD binding to the detergent extract and that MCD, as DTX<sub>I</sub> itself, inhibits  $^{125}\text{I}$ -DTX<sub>I</sub> binding. Half-maximal inhibitions of  $^{125}\text{I}$ -MCD binding were observed at  $K_{0.5} = 3.2$  nM for DTX<sub>I</sub> and at  $K_{0.5} = 0.56$  nM for MCD. Half-maximum inhibitions of  $^{125}\text{I}$ -DTX<sub>I</sub> binding were observed at  $K_{0.5} = 0.35$  nM for DTX<sub>I</sub> and  $K_{0.5} = 7.5$  nM for MCD. Other basic toxins that block other types of ionic channels such as apamin, which blocks  $\text{Ca}^{2+}$ -activated  $\text{K}^+$  channels (Hugues et al., 1982), or




FIGURE 2: (A and B) Effects of MCD and DTX<sub>I</sub> on peptide binding specific of  $^{125}\text{I}$ -DTX<sub>I</sub> and  $^{125}\text{I}$ -MCD to detergent extract from brain membranes. Binding of  $^{125}\text{I}$ -DTX<sub>I</sub> (84 pM) (A) or  $^{125}\text{I}$ -MCD peptide (79 pM) (B) to detergent extract (270  $\mu\text{g}/\text{mL}$  of protein) in the absence (control) or presence of DTX<sub>I</sub> ( $\bullet$ ), MCD peptide ( $\circ$ ), apamin ( $\blacksquare$ ), and ATX<sub>II</sub> ( $\blacktriangle$ ). (C) Sucrose gradient [3–20% (w/v)] centrifugation of solubilized  $^{125}\text{I}$ -DTX<sub>I</sub> ( $\bullet$ ) and  $^{125}\text{I}$ -MCD ( $\circ$ ) binding components. The arrow marks the position of catalase.

*Anemonia sulcata* toxin II, an effector of the voltage-dependent  $\text{Na}^+$  channel (Vincent et al., 1980), were without effect on the binding of both  $^{125}\text{I}$ -DTX<sub>I</sub> and  $^{125}\text{I}$ -MCD at concentrations as high as 1  $\mu\text{M}$  (Figure 2). The mast cell degranulating agent, compound 48/80 (50  $\mu\text{g}/\text{mL}$ ) was also without effect on binding of the two iodinated toxins. DTX<sub>I</sub> is a more potent inhibitor of  $^{125}\text{I}$ -MCD binding to synaptosomal membranes and brain sections than MCD itself (Bidard et al., 1987b). The order of potency is reversed after solubilization, suggesting that the allosteric interaction between DTX<sub>I</sub> and MCD binding sites is slightly different in the solubilized state.

**Receptors for  $^{125}\text{I}$ -DTX<sub>I</sub> and  $^{125}\text{I}$ -MCD Have Similar Stability and Similar Sedimentation Behaviors and Copurify.** Solubilization of both  $^{125}\text{I}$ -DTX<sub>I</sub> and  $^{125}\text{I}$ -MCD receptors in an active conformation requires the presence of  $\text{K}^+$  and  $\text{Rb}^+$  ions (Table I). Table I shows that conditions which stabilize one of the toxin receptors stabilize the other one to the same extent. The exchange of  $\text{K}^+$  for  $\text{Li}^+$ ,  $\text{Na}^+$ , or  $\text{Cs}^+$  ions in the solubilization procedure leads to disappearance of the binding activity for both ligands in parallel.

Figure 2C shows that the solubilized  $^{125}\text{I}$ -DTX<sub>I</sub> and  $^{125}\text{I}$ -MCD binding sites could not be separated in sucrose gradient centrifugation, indicating similar sedimentation coefficients. A reduction of the glycerol concentration in the gradient from 10 to 4% resulted in a higher migration speed. However, again no separation of the  $^{125}\text{I}$ -DTX<sub>I</sub> and  $^{125}\text{I}$ -MCD binding sites was observed (not shown).

Table I: Effects of Various Solubilization Conditions on the  $^{125}\text{I}$ -DTX<sub>1</sub> and  $^{125}\text{I}$ -MCD Peptide Binding Activity of Detergent Extracts of Rat Brain Membranes<sup>a</sup>

ion conditions during solubilization	$^{125}\text{I}$ -DTX bound (% of control)	$^{125}\text{I}$ -MCD bound (% of control)
control (120 mM KCl)	100 ± 2.0	100 ± 7.0
40 mM KCl	58 ± 2.6	68 ± 14.0
120 mM LiCl	<1	<1
120 mM NaCl	<1	4 ± 2.4
120 mM RbCl	62 ± 3.0	73 ± 6.3
120 mM CsCl	2 ± 0.6	<1
120 mM KCl, 1 mM EDTA	115 ± 3.6	116 ± 10.4

<sup>a</sup>Equal amounts of rat brain membranes were extracted with Triton X-100 in buffer A containing the indicated ions instead of 120 mM KCl (as described under Experimental Procedures). When EDTA (1 mM) was added, CaCl<sub>2</sub> and MgSO<sub>4</sub> were omitted. The binding activity of the extracts was then determined in buffer A. The data are given as mean ± SD from three experiments.

Although the complete purification of either  $^{125}\text{I}$ -DTX<sub>1</sub> or  $^{125}\text{I}$ -MCD binding components has not yet been carried out, a partial purification was obtained. Table II shows that  $^{125}\text{I}$ -DTX<sub>1</sub> and  $^{125}\text{I}$ -MCD binding sites copurify in two (independent) purification steps. Both sites seem to be located on acidic glycoproteins since they are retained on DEAE-Affi-Gel and on a WGA column.

**Labeling of  $^{125}\text{I}$ -MCD and  $^{125}\text{I}$ -DTX<sub>1</sub> Binding Sites Using Cross-Linking Experiments.** Cross-linking experiments with the two  $^{125}\text{I}$ -labeled toxins were carried out with DMS (Figures 3 and 4). Cross-linking experiments with  $^{125}\text{I}$ -MCD in the presence of different DMS concentrations identified a single polypeptide component of  $M_r$  80 000 (Figure 3, track h; Figure 4A, track a). Similar experiments with  $^{125}\text{I}$ -DTX<sub>1</sub> revealed the specific labeling of a single component of  $M_r$  83 000 (Figure 3, track k; Figure 4B, track a). At 2.5 mg/mL DMS, several minor components were labeled in addition to the main component at  $M_r$  83 000 (Figure 3, track l). However, at this cross-linker concentration, the electrophoretic pattern of membrane proteins was changed (not shown). The DMS concentration that was routinely used (0.5 mg/mL) did not produce detectable changes in the electrophoretic pattern of membrane proteins. No labeling was detected with denatured membranes (Figure 3, tracks a–d) or in conditions where membranes were omitted (Figure 3, tracks e–i).

Experiments shown in parts A and B of Figure 4 demonstrate the specificity of the covalent labeling obtained with  $^{125}\text{I}$ -MCD and  $^{125}\text{I}$ -DTX<sub>1</sub>. Incubation of brain membranes with  $^{125}\text{I}$ -MCD (Figure 4A) in the presence of increasing concentrations of unlabeled MCD (tracks a–c) or DTX<sub>1</sub> (tracks d–f) resulted in a concentration-dependent protection against the labeling of the  $M_r$  80 000 band. Covalent labeling of the band was abolished with 100 nM MCD (track c) or 10 nM DTX<sub>1</sub> (track e). Likewise, for  $^{125}\text{I}$ -DTX<sub>1</sub> cross-linking experiments (Figure 4B), increasing concentrations of unlabeled DTX<sub>1</sub> (tracks a–f) or MCD (tracks g–i) gave a concentration-dependent protection against the labeling of the  $M_r$  83 000 band.

Table II: Copurification of  $^{125}\text{I}$ -DTX and  $^{125}\text{I}$ -MCD Peptide Binding Sites<sup>a</sup>

	total protein (mg)	$^{125}\text{I}$ -DTX binding sites			$^{125}\text{I}$ -MCD peptide binding sites		
		sp act. <sup>b</sup>	recovery (%)	purification (x-fold)	sp act. <sup>b</sup>	recovery (%)	purification (x-fold)
detergent extract	115.6	64	100	1	37	100	1
eluate from DEAE-Affi-Gel blue	3.16	1115	47.4	17.3	831	60.7	22.2
eluate from WGA column	0.60	2327	18.8	36.1	992	16.3	31.5

<sup>a</sup>Binding assays with 6.5 fmol of  $^{125}\text{I}$ -DTX/assay and 7 fmol of  $^{125}\text{I}$ -MCD peptide/assay and column chromatographies performed as described under Experimental Procedures. <sup>b</sup>Specific activity is given in femtomoles per milligram of iodinated peptide bound.




FIGURE 3: Cross-linking of  $^{125}\text{I}$ -MCD or  $^{125}\text{I}$ -DTX<sub>1</sub> to rat brain membranes. Cross-linking experiments carried out with heat-denatured membranes (0.5 mg of protein boiled for 10 min) (tracks a and c,  $^{125}\text{I}$ -toxin alone; tracks b and d,  $^{125}\text{I}$ -toxin in the presence of the unlabeled toxin). Cross-linking under condition of absence of membranes (tracks e and i,  $^{125}\text{I}$ -toxin alone). In all these experiments, DMS was at 0.5 mg/mL. Tracks f–h ( $^{125}\text{I}$ -MCD) and j–l ( $^{125}\text{I}$ -DTX<sub>1</sub>) correspond to the labeling of intact membranes obtained with  $^{125}\text{I}$ -toxins in the presence of different DMS concentrations: 0 mg/mL (tracks f and j), 0.1 mg/mL (tracks g and k), and 2.5 mg/mL (tracks h and l).




FIGURE 4: Protection against cross-linking (0.5 mg/mL DMS) of  $^{125}\text{I}$ -MCD (panel A) or  $^{125}\text{I}$ -DTX<sub>1</sub> (panel B) to synaptic membranes by unlabeled MCD and DTX<sub>1</sub>. Membranes (0.5 mg of protein) were incubated with the  $^{125}\text{I}$ -labeled toxin in the presence of the indicated concentrations of unlabeled MCD or DTX<sub>1</sub>. The specifically labeled bands are indicated by arrows.

Cross-linking experiments with  $^{125}\text{I}$ -MCD were also carried out with disuccinimidyl suberate instead of DMS (data not shown). This treatment also incorporated  $^{125}\text{I}$ -MCD into a  $M_r$  80 000 band.

## DISCUSSION

Behavioral and electrocorticographic responses following intracerebroventricular injections of various doses of MCD

have shown that the peptide produces a quasi-permanent hippocampal  $\theta$  rhythm associated with an increase in the level of wakefulness before epileptic discharges are induced (Bidard et al., 1987a). The long-lasting quasi-permanent presence of  $\theta$  rhythm induced by MCD in the quiet and motionless animal seems to be unique to this bee venom toxin. This electrocorticographic response appears to be closely associated with the observation that a brief application of MCD to the CA<sub>1</sub> region of hippocampal slices induces long-term potentiation (Cherubini et al., 1987), i.e., a long-lasting increase in the efficacy of synaptic transmission considered to be related in some way to memory. For all these reasons, and also because MCD appears to have an endogenous equivalent in the brain (Cherubini et al., 1987), it appeared that it would be useful to have more information about the receptor site of this interesting bee venom peptide. The function of the MCD receptor is not well identified at the molecular level although preliminary information has been reported indicating that the peptide blocks voltage-dependent K<sup>+</sup> channels in hippocampal slices and nodose ganglia (Dolly et al., 1987).

More information is available concerning another family of excitatory polypeptide toxins extracted from the venom of snakes of the *Dendroaspis* species: dendrotoxins. Dendrotoxins facilitate transmitter release and induce repetitive firing (Harvey & Karlsson, 1982; Harvey & Anderson, 1985). The physiological effects of this type of toxin seem to be due to its potency to block voltage-dependent K<sup>+</sup> channels (Weller et al., 1985; Benoit & Dubois, 1986; Halliwell et al., 1986; Penner et al., 1986).

The observation has been made previously in this laboratory that DTX<sub>1</sub> inhibits <sup>125</sup>I-MCD binding both to brain membranes and to brain slices (Bidard et al., 1987b). This allosteric inhibition could have involved different receptor molecules with their mutual interaction necessitating the integrity of the membrane. This paper shows (i) that conditions of solubilization can be found with which one can preserve the binding activity of both <sup>125</sup>I-DTX<sub>1</sub> and <sup>125</sup>I-MCD with a high affinity and (ii) that inhibition of <sup>125</sup>I-MCD binding by DTX<sub>1</sub> persists in the solubilized state and that one can also observe in parallel inhibition by MCD of <sup>125</sup>I-DTX<sub>1</sub> binding. The latter observation suggests that both toxins bind to the same target that, considering the well-known action of DTX<sub>1</sub>, is associated with K<sup>+</sup> channel functioning. The conclusion that a single protein assembly is responsible for the binding of both <sup>125</sup>I-MCD and <sup>125</sup>I-DTX<sub>1</sub> is strengthened by a series of observations which have shown (i) that the activity of receptors for both toxins disappears in parallel in solubilization conditions in which K<sup>+</sup> or Rb<sup>+</sup> ions are replaced by Na<sup>+</sup>, Li<sup>+</sup>, or Cs<sup>+</sup> ions, (ii) that MCD and DTX<sub>1</sub> receptors have a similar sedimentation behavior in a sucrose gradient centrifugation, and (iii) that MCD and DTX<sub>1</sub> receptors copurify in a partial purification protocol.

Labeling of the MCD receptor has been achieved in cross-linking experiments with suberimidate derivatives. A specifically labeled polypeptide was identified with a  $M_r$  of  $80\,000 \pm 2000$ . Assuming the binding of one MCD ( $M_r$  2600) molecule per receptor, one then finds a  $M_r$  of  $77\,000 \pm 2000$  for the MCD receptor.

Dendrotoxin from *Dendroaspis angusticeps*, a less active analogue of DTX<sub>1</sub>, has been previously cross-linked to its protein receptor in chick synaptic membranes, and a complex with a  $M_r$  of 82 000 was observed (Black & Dolly, 1986). Results found in the present work with DTX<sub>1</sub> lead to the identification of a specifically labeled polypeptide chain of  $M_r$   $83\,000 \pm 2000$  in rat brain membranes. Again assuming a 1:1 relationship for the toxin ( $M_r$  7100)–receptor association,

one finds that the polypeptide chain that binds DTX<sub>1</sub> has a  $M_r$  of  $76\,000 \pm 2000$ .

Obviously there is a high similarity in molecular weights for the two polypeptides that serve as receptors for MCD and DTX<sub>1</sub>, respectively. Moreover, and as expected, cross-linking of <sup>125</sup>I-MCD to its receptor was prevented by DTX<sub>1</sub>, and cross-linking of <sup>125</sup>I-DTX<sub>1</sub> to its receptor was prevented by MCD. A first, simple explanation of these results would be that the same polypeptide chain of  $M_r$  76 000–77 000 contains binding sites for both MCD and DTX<sub>1</sub>. However, the possibility that the bee venom and the snake venom toxins bind to two different but sufficiently homologous polypeptide chains to have similar molecular weights cannot and should not be eliminated especially if there are two DTX<sub>1</sub> binding sites for one MCD binding site. The latter interpretation would imply that the two polypeptides are associated within the same protein complex to explain the allosteric interactions between MCD and DTX<sub>1</sub> receptors.

$\beta$ -Bungarotoxin is another snake toxin active on neurosecretion (Howard & Gundersen, 1980) that appears to block K<sup>+</sup> channels (Dreyer & Penner, 1987). Allosteric relationships between  $\beta$ -bungarotoxin, DTX<sub>1</sub>, and MCD binding sites have been observed (Schmidt et al., 1988), and the  $\beta$ -bungarotoxin binding site also needs K<sup>+</sup> for maintaining the binding conformation in the solubilized state (Rehm & Betz, 1984). It will be interesting to see, once the K<sup>+</sup> channel has been purified, how many different polypeptide chains are necessary to bind these three toxins.

The important aspect of the analysis of the properties of these toxins is their relationship with voltage-dependent K<sup>+</sup> channels. It is interesting to observe that a voltage-dependent K<sup>+</sup> channel from *Drosophila* has recently been cloned and sequenced. It corresponds to an inactivating A-type K<sup>+</sup> channel (Salkoff & Wyman, 1981; Papazian et al., 1987). The main constitutive chain of this channel has a  $M_r$  of 70 200, which is a molecular weight similar to that found for the DTX<sub>1</sub>/MCD binding component. It should be noted, however, that the *Drosophila* K<sup>+</sup> channel protein may undergo glycosylation. Also the functional K<sup>+</sup> channel may be a multimer of this polypeptide. It is not yet known whether MCD has any effect on A-type K<sup>+</sup> channels, but it has been previously demonstrated that dendrotoxin blocks A-type K<sup>+</sup> channels in CA<sub>1</sub> hippocampal neurons (Halliwell et al., 1986) and it is in hippocampus that the interaction between DTX<sub>1</sub> and MCD receptors is particularly potent (Bidard et al., 1987b).

#### ACKNOWLEDGMENTS

We thank J. Barhanin and M. Fosset for helpful discussions and C. Roulinat-Bettelheim for expert technical assistance.

#### REFERENCES

- Benoit, E., & Dubois, J. M. (1986) *Brain Res.* 377, 374–377.
- Bidard, J.-N., Gandolfo, G., Mourre, C., Gottesmann, C., & Lazdunski, M. (1987a) *Brain Res.* 418, 235–244.
- Bidard, J.-N., Mourre, C., & Lazdunski, M. (1987b) *Biochem. Biophys. Res. Commun.* 143, 383–389.
- Black, A. R., & Dolly, J. O. (1986) *Eur. J. Biochem.* 156, 609–617.
- Bruns, R. F., Lawson-Wendling, K., & Pugsbey, T. (1983) *Anal. Biochem.* 132, 74–81.
- Cherubini, E., Ben Ari, Y., Gho, M., Bidard, J.-N., & Lazdunski, M. (1987) *Nature (London)* 328, 70–73.
- Dolly, J. O., Stansfeld, C. E., Breeze, A., Pelchen-Matthews, A., Marsh, S. J., & Brown, D. A. (1987) in *Neurotoxins and Their Pharmacological Implications* (Jenner, P., Ed.) pp 81–96, Raven, New York.

- Dreyer, F., & Penner, R. (1987) *J. Physiol. (London)* 386, 455-463.
- Habermann, E. (1972) *Science (Washington, D.C.)* 177, 314-322.
- Halliwell, J., Othman, I., Pelchen-Matthews, A., & Dolly, J. O. (1986) *Proc. Natl. Acad. Sci. U.S.A.* 83, 493-497.
- Harvey, A., & Karlsson, E. (1982) *Br. J. Pharmacol.* 77, 153-161.
- Harvey, A., & Anderson, A. (1985) *Pharmacol. Ther.* 31, 33-55.
- Howard, B. D., & Gundersen, C. B. (1980) *Annu. Rev. Pharmacol. Toxicol.* 20, 307-336.
- Hugues, M., Romey, G., Duval, D., Vincent, J.-P., & Lazdunski, M. (1982) *Proc. Natl. Acad. Sci. U.S.A.* 79, 1308-1312.
- Laemmli, U. K. (1970) *Nature (London)* 227, 680-685.
- Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. J. (1951) *J. Biol. Chem.* 193, 265-275.
- Papazian, D., Schwartz, T., Tempel, B., Jan, Y., & Jan, L. (1987) *Science (Washington, D.C.)* 237, 749-753.
- Penner, R., Petersen, M., Pierau, F., & Dreyer, F. (1986) *Pfluegers Arch.* 407, 365-369.
- Rehm, H., & Betz, H. (1984) *J. Biol. Chem.* 259, 6865-6869.
- Salkoff, L., & Wyman, R. (1981) *Nature (London)* 293, 228-230.
- Schmidt, R., Betz, H., & Rehm, H. (1988) *Biochemistry* 27, 963-967.
- Schweitz, H. (1984) *Toxicol.* 22, 308-311.
- Taylor, J. W., Bidard, J.-N., & Lazdunski, M. (1984) *J. Biol. Chem.* 259, 13957-13967.
- Vincent, J.-P., Balerna, M., Barhanin, J., Fosset, M., & Lazdunski, M. (1980) *Proc. Natl. Acad. Sci. U.S.A.* 77, 1646-1650.
- Weller, U., Bernhardt, U., Siemen, D., Dreyer, F., Vogel, W., & Habermann, E. (1985) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 330, 77-83.

## Articles

### Site-Directed Mutagenesis of the T4 Endonuclease V Gene: Role of Lysine-130<sup>†</sup>

Adrian Recinos III<sup>‡</sup> and R. Stephen Lloyd\*<sup>§</sup>

Departments of Microbiology and Biochemistry and Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232

Received March 12, 1987; Revised Manuscript Received October 28, 1987

**ABSTRACT:** The DNA sequence of the bacteriophage T4 *denV* gene which encodes the DNA repair enzyme endonuclease V was previously constructed behind the hybrid  $\lambda$  promoter  $O_LP_R$  in a plasmid vector. The  $O_LP_R$ -*denV* sequence was subcloned in M13mp18 and used as template to construct site-specific mutations in the *denV* structural gene in order to investigate structure/function relationships between the primary structure of the protein and its various DNA binding and catalytic activities. The Lys-130 residue of the wild-type endonuclease V has been postulated to be associated with its apurinic endonuclease (AP-endonuclease) activity. The codon for Lys-130 was changed to His-130 or Gly-130, and each *denV* sequence was subcloned into a pEMBL expression vector. These plasmids were transformed into repair-deficient *Escherichia coli* (*uvrA recA*), and the following parameters were examined for cells or cell extracts: expression and accumulation of endonuclease V protein (K-130, H-130, or G-130); survival after UV irradiation; dimer-specific DNA binding; and kinetics of phosphodiester bond scission at pyrimidine dimer sites, dimer-specific *N*-glycosylase activity, and AP-endonuclease activity. The enzyme's intracellular accumulation was significantly decreased for G-130 and slightly decreased for H-130 despite normal levels of *denV*-specific mRNA for each mutant. On a molar basis, the endonuclease V gene products generally gave parallel levels of each of the catalytic and binding functions with K-130 > H-130 > G-130 >> control *denV*<sup>-</sup>. A surprising exception to this trend was that G-130, while low in dimer-specific binding capacity, demonstrated an AP-endonuclease function several times as efficient as that of the wild-type enzyme. Overall, these results suggest that the alterations of Lys-130 chiefly compromise the ability of the mutant enzymes to bind DNA at dimer sites. Dimer-specific binding, however, appears not to be required for the AP-endonuclease activity.

The product of the bacteriophage T4 *denV* gene is a DNA repair enzyme, endonuclease V, which functions in the removal of UV-induced pyrimidine dimer photoproducts. The enzyme performs the initial strand scission in the repair of these lesions by mechanisms which involve four sequential actions: (1) a

processive scanning process which monitors DNA for the presence of dimers; (2) a DNA binding function specific for dimer sites; (3) a pyrimidine dimer-DNA glycosylase (PD-glycosylase)<sup>1</sup> activity which cleaves the *N*-glycosyl bond be-

<sup>†</sup> This research was supported in part by NIH Grant ES 00267 and by a University Research Council Award, Vanderbilt University.

<sup>‡</sup> Department of Microbiology.

<sup>§</sup> Department of Biochemistry.

<sup>1</sup> Abbreviations: PD-glycosylase, pyrimidine dimer-DNA glycosylase; AP, apurinic or apyrimidinic; SDS, sodium dodecyl sulfate; Tris, tris-(hydroxymethyl)aminomethane; EDTA, ethylenediaminetetraacetic acid; RF, replicative form; kDa, kilodalton(s).